BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16360645)

  • 1. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds.
    Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI
    Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.
    Bergamo A; Masi A; Peacock AF; Habtemariam A; Sadler PJ; Sava G
    J Inorg Biochem; 2010 Jan; 104(1):79-86. PubMed ID: 19906432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
    Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
    Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity.
    Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E
    J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
    Aird RE; Cummings J; Ritchie AA; Muir M; Morris RE; Chen H; Sadler PJ; Jodrell DI
    Br J Cancer; 2002 May; 86(10):1652-7. PubMed ID: 12085218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
    Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
    Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
    Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
    J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
    Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
    J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion.
    Bergamo A; Stocco G; Casarsa C; Cocchietto M; Alessio E; Serli B; Zorzet S; Sava G
    Int J Oncol; 2004 Feb; 24(2):373-9. PubMed ID: 14719114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds.
    Karki SS; Thota S; Darj SY; Balzarini J; De Clercq E
    Bioorg Med Chem; 2007 Nov; 15(21):6632-41. PubMed ID: 17765549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
    Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
    Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
    Peacock AF; Parsons S; Sadler PJ
    J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
    Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
    J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.